US taxpayers paid for remdesivir's development, so why will Gilead get all the profit?

(Natural News) To make progress with remdesivir, the drug that’s buoyed expectations for the treatment of the Wuhan coronavirus (COVID-19), Gilead Sciences needed help from American taxpayers, getting assistance from three federal health agencies. Despite this, the federal agencies have not asserted patent rights to the drug, meaning that Gilead will have little constraint when...

from NaturalNews.com https://ift.tt/3erP88I